NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Friday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO opened at $4.15 on Friday. The company has a market capitalization of $8.35 million, a price-to-earnings ratio of -0.66 and a beta of 2.29. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $5.60. The business’s 50-day moving average is $3.73 and its 200-day moving average is $3.85.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. The business had revenue of $0.77 million during the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.